1994
Arrest of Motor Neuron Disease in wobbler Mice Cotreated with CNTF and BDNF
Mitsumoto H, Ikeda K, Klinkosz B, Cedarbaum J, Wong V, Lindsay R. Arrest of Motor Neuron Disease in wobbler Mice Cotreated with CNTF and BDNF. Science 1994, 265: 1107-1110. PMID: 8066451, DOI: 10.1126/science.8066451.Peer-Reviewed Original ResearchConceptsBrain-derived neurotrophic factorCiliary neurotrophic factorMotor neuron diseaseNeurotrophic factorNeuron diseaseWobbler miceMotor neuron dysfunctionNeuron dysfunctionDisease progressionSubcutaneous injectionMotor neuronsHistological criteriaAnimal modeAnimal modelsAlternate daysSignaling pathwaysDiseaseMiceCellular signaling pathwaysProgressionDysfunctionFactorsCotreatmentNeuronsAdministration
1993
The effect of L-dopa infusions with and without phenylalanine challenges in parkinsonian patients: plasma and ventricular CSF L-dopa levels and clinical responses.
Woodward WR, Olanow CW, Beckner RM, Hauser RA, Gauger LL, Cedarbaum JM, Nutt JG. The effect of L-dopa infusions with and without phenylalanine challenges in parkinsonian patients: plasma and ventricular CSF L-dopa levels and clinical responses. Neurology 1993, 43: 1704-8. PMID: 8414016, DOI: 10.1212/wnl.43.9.1704.Peer-Reviewed Original ResearchConceptsL-DOPAMotor responseLarge neutral amino acidsVentricular CSF concentrationsAdvanced Parkinson's diseaseL-DOPA infusionL-DOPA levelsClinical responseParkinsonian patientsCSF concentrationsOral administrationNeutral amino acidsParkinson's diseaseInfusionPatientsPhenylalanine challengeReliable predictorCSFVDiseaseBrainDurationResponsePlasmaLevelsAdministrationAdministration of the new COMT inhibitor OR‐611 increases striatal uptake of fluorodopa
Guttman M, Léger G, Reches A, Evans A, Kuwabara H, Cedarbaum JM, Gjedde A. Administration of the new COMT inhibitor OR‐611 increases striatal uptake of fluorodopa. Movement Disorders 1993, 8: 298-304. PMID: 8341294, DOI: 10.1002/mds.870080308.Peer-Reviewed Original ResearchConceptsPositron emission tomographyNew COMT inhibitorL-DOPACOMT inhibitorsTreatment of patientsStriatal uptakeBrain uptakeBrain 6Cynomolgus monkeysParkinson's diseaseL-dopa analogEmission tomographyPromising agentSame animalsPET measurementsDiseaseMetabolismInhibitorsControl statePretreatmentPatientsFluorodopaAdjunctAdministrationUptake
1992
3‐O‐methyldopa administration does not alter fluorodopa transport into the brain
Guttman M, Léger G, Cedarbaum J, Reches A, Woodward W, Evans A, Diksic M, Gjedde A. 3‐O‐methyldopa administration does not alter fluorodopa transport into the brain. Annals Of Neurology 1992, 31: 638-643. PMID: 1514775, DOI: 10.1002/ana.410310611.Peer-Reviewed Original ResearchConceptsChronic L-DOPA therapyAdvanced Parkinson's diseaseL-dopa therapyPositron emission tomographic studiesL-DOPA administrationEmission tomographic studiesPositron emission tomographyL-dopa preparationsParkinsonian patientsPlasma concentrationsCynomolgus monkeysParkinson's diseasePatientsEmission tomographyL-DOPABrainTomographic studiesDiseaseAdministrationInfusionTherapyBlood
1991
Reduction of Circulating 3-O-Methyldopa by Inhibition of Gatechol-O-Methyltransferase With OR-611 and OR-462 in Cynomolgus Monkeys: Implications for the Treatment of Parkinson's Disease.
Cedarbaum J, Leger G, Guttman M. Reduction of Circulating 3-O-Methyldopa by Inhibition of Gatechol-O-Methyltransferase With OR-611 and OR-462 in Cynomolgus Monkeys: Implications for the Treatment of Parkinson's Disease. Clinical Neuropharmacology 1991, 14: 330. PMID: 1913700, DOI: 10.1097/00002826-199108000-00005.Peer-Reviewed Original Research
1990
Effect of Nitecapone (OR-462) on the Pharmacokinetics of Levodopa and 3-O-Methyldopa Formation in Cynomolgus Monkeys.
Cedarbaum JM, Léger G, Reches A, Guttman M. Effect of Nitecapone (OR-462) on the Pharmacokinetics of Levodopa and 3-O-Methyldopa Formation in Cynomolgus Monkeys. Clinical Neuropharmacology 1990, 13: 544. PMID: 2276119, DOI: 10.1097/00002826-199012000-00006.Peer-Reviewed Original ResearchConceptsCynomolgus monkeysEffect of nitecaponePeripheral COMT inhibitorSingle-dose studyPharmacokinetics of levodopaBlood-brain barrierConcentration-time curveLevodopa administrationPlasma pharmacokineticsCOMT inhibitorsAdverse physiological effectsFurther inhibitionLevodopaDoseNitecaponePhysiological effectsMonkeysPharmacokineticsNovel inhibitorsInhibitorsInhibitionCarbidopaAdministrationSustained enteral administration of levodopa increases and interrupted infusion decreases levodopa dose requirements.
Cedarbaum J, Silvestri M, Kutt H. Sustained enteral administration of levodopa increases and interrupted infusion decreases levodopa dose requirements. Neurology 1990, 40: 995-7. PMID: 2345621, DOI: 10.1212/wnl.40.6.995.Peer-Reviewed Original ResearchConceptsInterrupted infusionTherapeutic response fluctuationsStriatal dopamine receptorsContinuous enteral infusionLevodopa dose requirementEnteral administrationEnteral infusionContinuous infusionDopamine receptorsInfusion rateParkinson's diseaseDose requirementsInfusionResponse fluctuationsMotor performanceLevodopaDiseasePatientsAdministrationReceptors